Welcome to our dedicated page for ADC Therapeutics SA SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ADC Therapeutics SA filings document the regulatory record of a Swiss commercial-stage biotechnology company with common shares listed on the New York Stock Exchange. Its Form 8-K reports cover operating results, preliminary financial information, Regulation FD presentations, clinical data updates for ZYNLONTA studies, and material agreements including amendments to royalty financing arrangements.
Proxy materials describe annual general meeting matters under Swiss law, including approval of annual and consolidated financial statements, compensation report votes, discharge of directors and executive committee members, board and compensation committee elections, auditor matters and share capital governance. The filings also identify the company’s registered common shares, par value and exchange listing.
BlackRock, Inc. reports a significant ownership position in ADC Therapeutics SA common stock. BlackRock and certain of its business units beneficially own 6,857,815 shares of ADC Therapeutics, representing 5.4% of the outstanding common stock.
BlackRock has sole voting power over 6,765,332 shares and sole dispositive power over all 6,857,815 shares, with no shared voting or dispositive power reported. Various underlying clients and investors have the right to receive dividends and sale proceeds from these shares, but no single such person holds more than five percent of ADC Therapeutics’ total outstanding common shares. The filing is signed by Managing Director Spencer Fleming on behalf of BlackRock.
Zaki Mohamed reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics SA Chief Medical Officer Zaki Mohamed received an equity award in the form of restricted stock units. On June 30, 2026 he was granted 213,900 RSUs, each representing the right to receive one common share at no purchase price.
The RSUs will vest on the earlier of June 30, 2027 or a qualifying termination without cause or for good reason, provided he remains employed through the vesting date. Following this grant, Mohamed holds 896,317 common shares directly, highlighting that this is a compensation-related award rather than an open-market share purchase or sale.
GRAHAM PETER J reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics disclosed that Chief Legal Officer Peter J. Graham received an award of 221,100 restricted stock units (RSUs) of common shares on June 30, 2026 under an incentive award letter agreement. The RSUs vest on the earlier of June 30, 2027 or certain termination events, subject to continued employment. Each RSU represents a right to receive one common share, bringing his direct holdings to 841,640 common shares after the award.
ADC Therapeutics reported that its Chief Financial Officer, Jose Carmona, received an award of 203,700 restricted stock units on June 30, 2026. These RSUs vest on the earlier of June 30, 2027 or certain qualifying termination events, assuming continued employment. Each RSU converts into one common share, bringing his direct holdings to 938,076 common shares after the award.
MALLIK AMEET reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics SA reported that Chief Executive Officer Ameet Mallik received an equity compensation award in the form of 675,000 restricted stock units on June 30, 2026. These RSUs vest upon the earlier of June 30, 2027 or certain qualifying terminations of employment, conditioned on continued service. Following the grant, Mallik directly holds 2,121,769 common shares.
ADC Therapeutics approved one-time retention awards for key executives to encourage them to stay with the company. On June 30, 2026, the board, advised by its independent compensation consultant, granted cash bonuses payable on or about July 15, 2026 and restricted stock units (RSUs) that vest after one year or upon certain terminations.
CEO Ameet Mallik will receive a cash incentive of $1,795,500 and 675,000 RSUs, CFO Jose Carmona will receive $541,842 and 203,700 RSUs, and Chief Medical Officer Mohamed Zaki will receive $568,974 and 213,900 RSUs. Executives must generally remain employed through June 30, 2027 to keep the cash awards and for RSUs to vest, except if they are terminated without cause or resign for good reason.
ADC Therapeutics is implementing a strategic reorganization centered on its ZYNLONTA franchise, including a global workforce reduction of approximately 17 percent. This move is tied to the expected completion of the LOTIS-5 and LOTIS-7 trials and to operational efficiencies.
The company expects the reorganization to generate annualized estimated cost savings of about $10 million, while incurring one-time pre-tax charges of roughly $3 million for severance, benefits and related termination costs, mostly in the second quarter of 2026. Management states it has an expected cash runway at least into 2028 and is preparing for an August 2026 pre-sBLA meeting with the FDA for LOTIS-5, with an sBLA submission planned for the fourth quarter of 2026 and full LOTIS-7 data anticipated by the end of 2026.
ADC Therapeutics SA director Robert Azelby reported routine equity compensation and related tax withholding. On June 1, 2026, he received a grant of 45,000 Common Share RSUs under the 2019 Equity Incentive Plan for his service as a director, vesting at the earlier of one year from grant or the 2027 annual meeting. On June 3, 2026, 12,600 Common Shares were withheld by the company at $3.08 per share to satisfy tax obligations from previously vested RSUs. After these transactions, Azelby directly holds 112,805 Common Shares.
ADC Therapeutics SA director Ron Squarer reported routine equity compensation and related tax withholding. On June 1, 2026, he received an annual grant of 45,000 restricted stock units for board service under the 2019 Equity Incentive Plan, with each RSU representing one common share upon vesting.
On June 3, 2026, 15,196 common shares were withheld by the company to cover his tax obligations when previously granted RSUs vested, at a reference price of $3.08 per share. After these transactions, he holds 123,431 common shares directly.
ADC Therapeutics director Sandor Victor reported routine equity compensation and related tax withholding. On June 1, 2026, he received 45,000 Common Shares through a grant of restricted stock units under the 2019 Equity Incentive Plan at a stated price of $0.00 per share. These RSUs vest on the earlier of one year from grant or the 2027 Annual Meeting of Shareholders, subject to continued board service. On June 3, 2026, the company withheld 12,600 Common Shares at $3.08 per share to cover his tax obligations upon vesting of previously granted RSUs, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Victor directly owns 140,686 Common Shares of ADC Therapeutics.